Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$3.00 - $4.00
Shares Offered
3,333,334
Deal Size
$11.67M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 40.34M
Revenue (ttm) n/a
Net Income (ttm) -1.42M
Shares Out 11.53M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About APUS

Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 2
Stock Exchange NYSEAMERICAN
Ticker Symbol APUS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Inflammation-focused biotech Apimeds Pharmaceuticals US files for a $12 million IPO

Apimeds Pharmaceuticals US, a clinical stage biotech developing a bee venom-based treatment for inflammation, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering.

3 months ago - Renaissance Capital

Apimeds Pharmaceuticals US IPO Registration Document (S-1)

Apimeds Pharmaceuticals US has filed to go public with an IPO on the NYSE American

3 months ago - SEC